-
-
-
In a randomized, prospective trial, anemic chemotherapy-receiving patients received either darbepoetin alone or darbepoetin with intravenous ferric gluconate. The group that received the added ferric gluconate had a significantly higher rate of achieving objective criteria for anemia improvement. The iron infusions were associated with no observed toxicity.
-
Hypereosinophilic syndrome (HES) is a spectrum of diseases where a primary cause of eosinophilia can not be identified.
-
For premenopausal ER+ breast cancer patients receiving CMF chemotherapy in an adjuvant setting, the presence of anemia during treatment was found to be a significant risk factor for the development of local recurrence.
-
FDA drug approval to change? Urinary incontinence in women; how metabolism of certain drugs can be predicted by genetic analysis; bowel preps may compromise renal function especially in the elderly according to a new study; FDA Actions.
-
The Women's Health Initiative (WHI) is a randomized controlled trial which is evaluating cancer and disease risk among healthy menopausal women aged 50-79 years.
-
-
By Alison Edelman, MD, MPH, Assistant Professor, Assistant Director of the Family Planning Fellowship Department of Obstetrics & Gynecology, Oregon Health & Science University, Portland, is Associate Editor for OB/GYN Clinical Alert.
-
The primary purpose of this phase III study was to determine if maintenance of hemoglobin values above 12 g/dL by use of R-HUEPO during chemoradiotherapy (weekly cisplatin) for advanced cervix cancer was associated with improved outcomes (progression-free and overall survival and local control rates) relative to maintenance of hemoglobin values above 10 g/dL by way of non-R-HUEPO methods.
